Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial is studying the side effects and best dose of veliparib when given
together with carboplatin and paclitaxel in treating patients with advanced solid cancer.
Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell
growth. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different
ways to stop the growth of tumor cells, either by killing the cells or by stopping them from
dividing. Giving veliparib together with carboplatin and paclitaxel may help kill more tumor
cells.